A PHASE 4, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY ANDSAFETY OF VARENICLINE COMPARED TO PLACEBO FOR SMOKINGCESSATION THROUGH REDUCTION - Reduce to Quit

Pfizer Inc.235 East 42nd Street, New York, NY 100170 个研究点目标入组 1,404 人开始时间: 2011年5月11日最近更新: 2013年10月28日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 1,404

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
•2. Male and female cigarette smokers over the age of 18 years who are not willing/able to quit smoking within the next month but who are willing to attempt to reduce their smoking to work toward a quit attempt within the next 3 months.
•3. Subjects must have smoked an average of at least 10 cigarettes per day during the past year and during the month prior to the screening visit, with no continuous period of abstinence greater than 3 months in the past year and who have an exhaled carbon monoxide (CO) >10 ppm at screening.
•4. Subjects with history of lifetime or current mild to moderate (investigator opinion) major depressive disorder (MDD), depression, depressed mood, anxiety, and anxiety disorders (including general anxiety disorder (GAD), obsessive compulsive disorder (OCD) and phobias such as agoraphobia and social phobia) may be included if their condition is stable. Stability is defined as:
•If on medication, on the same dose for the past 6 months;
•No hospitalizations for exacerbations in the past 6 months.
•5. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
•6. Females who are not of childbearing potential (ie, who are surgically sterilized or at least 2 years postmenopausal) and who are not nursing may be included. Females who are of childbearing potential may be included provided that they are not pregnant, not nursing, and who meet all of the following criteria:
•Are instructed and agree to avoid pregnancy through 30 days after the last dose of study medication;
•Have a negative pregnancy test (beta-hCG) at Screening and Baseline and agree to use at least one of the birth control methods listed below:
•An oral contraceptive agent, an intrauterine device (IUD), an implantable
•contraception (eg, Norplant), or an injectable contraceptive (eg, Depo Provera) for at least 1 month prior to entering the study and will continue it's
•use through at least 30 days after the last dose of study medication; or:
•A double barrier method of contraception, (ie condom plus spermicide in
•combination with a female condom, diaphragm, cervical cap, or intrauterine
•device) or sexual abstinence prior to entering into the study and for at least
•least 30 days after the last dose of study drug
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1334
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 70

排除标准

•1. Subjects with a history of a suicide attempt or any suicidal behavior in the past two years as assessed using the C-SSRS and/or the SBQ- R.
•History of suicidal ideation with intent/plan in the past 6 months (yes” to
•Questions 4 and/or 5 on the C-SSRS) or at the screening or baseline visit.
•2. Subjects with lifetime or current severe major depressive disorder (MDD),
•depression, depressed mood, anxiety, or anxiety disorder (including generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD), and phobias such as agoraphobia and social phobia).
•3. Subjects with unstable mild to moderate major depressive disorder (MDD), depression, depressed mood, anxiety, or anxiety disorder (including generalized anxiety disorder (GAD), obsessive compulsive disorder (OCD),and phobias) such as agoraphobia and social phobia
•4. Subjects with a lifetime diagnosis or treatment for psychosis, panic disorder, bipolar disorder, post traumatic stress disorder (PTSD), or schizophrenia.
•5. Subjects with alcohol or substance abuse or dependence (except nicotine) unless in full remission for at least 12 months.
•6. Subjects with a positive urine drug screen (at screening or baseline) for drugs of abuse/potential abuse not prescribed for the treatment of a medical condition.
•7. Subjects previously enrolled in a study that included varenicline (CP-526,555) or subject who have previously taken Chantix®/ Champix®. Subjects who have taken a very limited number of prescription doses may be considered pending discussion with the study clinician.
•8. Subjects who have participated in other studies within 30 days prior to the screening visit of this study or any time during this study.
•9. Subject with an SGOT (AST) or SGPT (ALT) greater than 3 times the upper limit of normal (ULN) or total bilirubin greater than 2 times the ULN at screening.
•10. Subjects having clinically significant medical disorders or clinically significant laboratory test abnormalities as determined by the Principal Investigator.
•11. Subjects with severe chronic obstructive pulmonary disease (COPD) defined as any subject who fulfills any of the following criteria:
•History of repeated exacerbations of COPD (greater than or equal to 3 in 3 years).
•Requires systemic corticosteroid maintenance (eg, oral prednisolone) for
•management of chronic symptoms.
•Is maintained on oxygen therapy for management of chronic symptoms.
•12. Subjects with a recent (<5 years) history of cancer. Subjects with completely excised carcinoma in situ of the cervix or completely excised melanomas <5 years prior to screening may be considered pending discussion with the study clinician. Subjects with a remote (>5 years) history of cancer may be considered pending discussion with the study clinician.
•Subjects with cured basal cell or squamous cell carcinoma of the skin are allowed.
•13. Subjects with evidence or history of clinically significant allergic reactions to drugs (eg, anaphylaxis or Stevens-Johnson syndrome).
•14. Subjects with a clinically significant ECG at the screening visit (as determined by the Principal Investigator or medically appropriate designee).
•15. Subjects with clinically significant cardiovascular disease in the past 2 months.
•Examples of clinically significant cardiovascular disease include:
•Myocardial infarction;
•Coronary artery bypass graft (CABG);
•Percutaneous transluminal coronary angioplasty (PTCA);
•Severe or unstable angina;
•Serious arrhythmia;
•Clinically significant ECG

研究者

发起方

Pfizer Inc.235 East 42nd Street, New York, NY 10017

相似试验

进行中（未招募）

1 期

Study safety and effectiveness of a reduce to quit approach using varenicline versus placeboSmoking CessationMedDRA version: 14.0Level: LLTClassification code 10008374Term: Cessation of smokingSystem Organ Class: 10041244 - Social circumstances

EUCTR2010-021788-33-GBPfizer Inc.235 East 42nd Street, New York, NY 100171,404

进行中（未招募）

不适用

Study safety and effectiveness of a reduce to quit approach using varenicline versus placeboSmoking CessationMedDRA version: 14.1Level: LLTClassification code 10008374Term: Cessation of smokingSystem Organ Class: 100000004869

EUCTR2010-021788-33-DEPfizer Inc.235 East 42nd Street, New York, NY 10017 US1,404

进行中（未招募）

不适用

A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg pMDI WITH HFA-134A PROPELLANT (CHF1535, FOSTER®) VERSUS FLUTICASONE 250 µg PLUS SALMETEROL 50 µg DPI (SERETIDE® DISKUS®) AS MAINTENANCE TREATMENT IN CONTROLLED ASTHMATIC PATIENTS. - FACTO studyMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaAsthma

EUCTR2008-003740-11-DEChiesi Farmaceutici S.p.A.452

已完成

4 期

NL-OMON33799Chiesi Farmaceutici110

进行中（未招募）

不适用

EUCTR2008-003740-11-NLChiesi Farmaceutici S.p.A.452